Mouth Cancer - A Deadly Disease - On the Increase
Prne
November 5th, 2009
LONDON -
- With Photo
Mouth cancer (also called oral cancer) is a malignant growth which can occur in any part of the mouth including the lips and tongue. In the UK, the numbers of new cases have risen by over 41 per cent over the last ten years(1). About 5,325 people get cancer of the mouth each year and the disease kills one person every five hours. Treated in its early stages, mouth cancer is curable but if not detected early, it kills around one in two sufferers.
Anyone can be affected by mouth cancer, whether they have their own teeth or not. Smoking, or chewing tobacco (or betel quid/paan/gutkha), greatly increases your chances of getting mouth cancer. Heavy drinking is also a risk. If you do both, your chances of getting mouth cancer are much greater. This cancer is more common in men than women and more likely to occur in people age 40 years and older. Experts today, however, are concerned about rising numbers of this cancer in younger age groups. The HPV virus from sexual contact is believed to account for this.
Mouth cancers often appear as a painless mouth ulcer that does not heal normally or, less often, as a red or white patch in the mouth. Dental Authorities seek to encourage people to understand their level of risk for the disease and to advise dentists to be vigilant in their examination procedures. A dentist is trained and in the best position to examine for early signs of this disease.
The routine dental examination procedure is quick, simple, completely painless and requires no injection. The dentist carefully examines the inside of the mouth with the help of a small mirror. Remember, the dentist is able to see parts of your mouth that you cannot see easily yourself.
Many UK dental practices now offer a mouth cancer screening service which aims to increase your awareness of your own level of risk for the disease and to help you reduce that risk by changing your lifestyle habits.
In addition to this lifestyle counselling and regular screening, dental practices can now offer patients an extended test using a new mouth cancer screening system which can identify abnormal areas of the mouth, identifying areas of potential risk even before they become cancer. The latest system is called ViziLite Plus which is used extensively in the USA as an aid to early detection and has been widely introduced into the UK.
If you drink heavily, smoke or use tobacco in any form, you may be at high risk. You are advised to contact your dentist, doctor or pharmacist if you have any concerns. If in doubt - get checked out.
Note to Editors:
A picture accompanying this release is available through the PA Photowire. It can be downloaded from www.pa-mediapoint.press.net or viewed at www.mediapoint.press.net or www.prnewswire.co.uk.
For more information visit www.mouthcancer.org ViziLite Plus is a registered trademark of Zila Inc, USA www.zila.com Reference (1) Cancer Research UK (2009) UK oral cancer mortality statistics.
Source: Scope Dental Professional Relations
Filed under Business, Health, Health Care / Hospitals, Pharmaceuticals, Surveys / Polls / Research | Tags: London, Scope Dental Professional Relations, United Kingdom | Comment Below
Related Press Releases Clinical Genomics Continues Collaborative Research With CSIROOctober 6th, 2009 SYDNEY -
Sydney-based Clinical Genomics Pty Ltd and CSIRO have entered into a new phase in their collaboration to develop improved diagnostics for cancers of the colon and rectum (bowel cancer). In an earlier research program, Clinical Genomics and researchers from CSIRO's Preventative Health Flagship used advanced genomics and mathematics to identify a number of biomarker genes capable of differentiating between bowel cancer tissue, even at its very earliest stages, and normal bowel tissue. Call to Action to Prevent Deaths From Prostate Cancer in EuropeSeptember 16th, 2009 ANTWERP, Belgium -
- Leading Cancer Groups and Archbishop Desmond Tutu Unite in Call to Action in the Fight Against Prostate Cancer
ANTWERP, Belgium, September 17 /PRNewswire/ --
A coalition of influential European advocacy and professional groups are meeting today to call for action by the European Parliament to commit to serious steps to reduce the number of men affected by, and dying from prostate cancer, by ensuring timely access to information, care and support services for men at risk or with prostate cancer. The call to action is being launched during European Urology Week, as part of a new campaign, the Proactive Prostates Initiative, at a meeting in Antwerp, which is being hosted by Europa Uomo and the European Association of Urology. CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical ResearchAugust 3rd, 2009 EINDHOVEN, The Netherlands - With today's final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) medical research, making CTMM one of the largest public-private partnerships in the world. This pivotal point in the organisation's development firmly positions the Netherlands as one of the world's leading destinations for translational biomedical research. Bone Cancer Research Trust Calls for New Treatments for Bone CancerJune 17th, 2009 LONDON - The Bone Cancer Research Trust is calling for new treatments for bone cancers affecting children and young people. This includes osteosarcoma and Ewing's sarcoma, the two most common forms of primary bone cancer. Advance in Bowel Cancer Test ResearchJune 4th, 2009 SYDNEY - Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls. Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions. Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck CancerMay 29th, 2009 MADRID - Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone -
The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC). The endpoint of Time-to-Treatment Failure was defined as a composite of time-to-disease progression, -to-surgery or other cancer-related treatments, -to-drop-out due to an adverse event, and to death from any cause. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar ABMay 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer TestingApril 28th, 2009 SYDNEY - To Receive Milestone Payments from Quest Diagnostics
Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after successfully achieving key research and development goals. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USAApril 13th, 2009 UPPSALA, Sweden - Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan Drug designation can entail additional assistance from FDA to expedite and optimize drug development and upon approval a seven year market exclusivity is granted. PSA Screening Cuts Deaths by 20%, Says World's Largest Prostate Cancer StudyMarch 17th, 2009 STOCKHOLM, Sweden - Attn: Healthcare Editors
Screening for prostate cancer can reduce deaths by 20%, according to the
results of the European Randomized Study of Screening for Prostate Cancer
(ERSPC) published online 1700 hours CET 18 March (NEJM, Online First*). ERSPC
is the world's largest prostate cancer screening study and provides robust,
independently- audited evidence, for the first time, of the effect of
screening on prostate cancer mortality.
Related News Cancer spreads to Jade Goody's brainMarch 4th, 2009 LONDON - Terminally ill British reality TV star Jade Goody underwent a surgery Monday after her cancer rampaged uncontrollably throughout her body and even hit her brain. The disease, which started in her cervix last year, has already been found in her liver, groin and bowel, reports thesun.co.uk. Bates regrets not making cancer battle publicJanuary 5th, 2009 LONDON - Oscar winning actress Kathy Bates regrets not making her battle with ovarian cancer public. Contactmusic.com reports that Bates has now signed up as Ovarian Cancer Foundation spokeswoman. Applegate's sense of humour helped her cope with cancerMarch 25th, 2009 WASHINGTON - Hollywood actress Christina Applegate, who was diagnosed with breast cancer last year, has revealed that it was her sense of humour that helped her cope with the disease. Applegate tells that "the only way to cope" with the disease was laughing throughout the painful treatment. Cancer-stricken Farrah Fawcett 'hospitalized'April 6th, 2009 WASHINGTON - Farrah Fawcett, the actress who has been fighting cancer for almost three years, has reportedly been admitted to a Los Angeles hospital. According to sources, the 62-year-old former star of 'Charlie's Angels' is critical but stable. Five-term Sen. Chris Dodd diagnosed with prostate cancerJuly 31st, 2009 Dodd has prostate cancerWASHINGTON — Sen. Christopher Dodd, D-Conn., has been diagnosed with an early stage of prostate cancer and intends to have surgery early in August, his office said Friday. 60-year-old drug may help treat deadly cancersAugust 27th, 2009 WASHINGTON - A drug developed back in 1940s has a potential to treat some of the most deadly cancers, it has emerged. Scientists from Institute of Cancer Research in London have discovered that methotrexate, a chemotherapy treatment invented in the 1940s, has the potential to work against a genetic fault called HNPCC. Abhishek Bachchan propagates cancer awareness with election campaignApril 9th, 2009 MUMBAI - Bollywood actor Abhishek Bachchan used a cancer-awareness programme to call upon electorates to cast their ballot in the upcoming general elections. "I was being told that as per a statistic out of 250 million young urban voters in the last election 16 per cent voted. Study: Tanning beds and UV radiation as deadly as arsenic, mustard gas, experts sayJuly 29th, 2009 Study: Tanning beds as deadly as arsenicLONDON — International cancer experts have moved tanning beds and other sources of ultraviolet radiation into the top cancer risk category, deeming them as deadly as arsenic and mustard gas. For years, scientists have described tanning beds and ultraviolet radiation as "probable carcinogens."
A new analysis of about 20 studies concludes the risk of skin cancer jumps by 75 percent when people start using tanning beds before age 30. 'Jade Goody effect' sends women rushing to UK's NHS for cervical testsApril 27th, 2009 LONDON - A record number of women have been rushing to the UK's National Health Service (NHS) for cervical smear tests since Jade Goody lost her life to the disease on March 22. According to Sara Hiom from Cancer Research UK, the tragic demise of the late reality star, who passed away aged 27, had sent the number of examinations soaring sky high. Darth Vader battling prostate cancerMarch 18th, 2009 LONDON - Legendary actor David Prowse has revealed that he is battling prostate cancer. David, who thrilled fans with his terrific portrayal of the villain Darth Vader in the 'Star Wars' trilogy, has been undergoing radiotherapy for nearly two months.
|
|
